IP Library › Granted Patent US 12,570,978
Granted Patent B2
US 12,570,978 · App. 18/052,785 · Granted Mar 10, 2026

Methods and compositions for macrophage polarization

Inventors: Sriram Sathyanarayanan (Lexington, MA); Douglas E. Williams (Boston, MA); Dalia Burzyn (Newton, MA); Adam Thomas Boutin (Cambridge, MA); Sushrut Kamerkar (Cambridge, MA)
Assignee: LONZA SALES AG
C12N15/1135A61K9/5068C12N15/113A61K45/06C12N2310/11C12N2310/321C12N2310/3515C12N2320/32
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,570,978
App. No.
18/052,785
Granted
Mar 10, 2026
Kind
B2
Abstract

Disclosed herein are compositions and methods comprising extracellular vesicles comprising nucleic acid that target genes, leading to macrophage polarization of tumor associated macrophages. In certain embodiments, disclosed herein are methods and compositions for increasing macrophage polarization for the treatment of cancer.

Claims (16)

1 . An extracellular vesicle comprising one or more immunomodulating component(s) that, upon contact with a macrophage, selectively repolarizes the macrophage from an M2 to an M1 phenotype,

wherein the one or more immunomodulating components comprises a single-stranded antisense oligonucleotide (ASO),

having a sequence at least 95% identical to SEQ ID NO: 1;

having a sequence at least 95% identical to SEQ ID NO: 2; or

having a sequence at least 95% identical to SEQ ID NO: 4.

2 . The extracellular vesicle of claim 1 , wherein the extracellular vesicle is an exosome.

3 . The extracellular vesicle of claim 1 , further comprising an additional immunomodulating component.

4 . The extracellular vesicle of claim 3 , wherein the additional immunomodulating component is a small molecule drug, an antibody or active fragment thereof, or a therapeutic protein or active fragment thereof.

5 . The extracellular vesicle of claim 4 , wherein the antibody or active fragment thereof is an immune checkpoint inhibitor that binds to CTLA-4, PD-1, or PD-L1 or an inhibitor that binds to CSF1-R.

6 . The extracellular vesicle of claim 5 , wherein the antibody or active fragment thereof comprises CDRs that are at least 95% identical to the CDRs of Ipilimumab, or at least 95% identical to the CDRs of Nivolumab, or at least 95% identical to the CDRs of Cemiplimab, or at least 95% identical to the CDRs of Pembrolizumab, or at least 95% identical to the CDRs of Atezolizumab, or at least 95% identical to the CDRs of Avelumab, or at least 95% identical to the CDRs of Durvalumab, or at least 95% identical to the CDRs of Pexidartinib, or at least 95% identical to the CDRs of PLX7486, or at least 95% identical to the CDRs of ARRY-382, or at least 95% identical to the CDRs of JNJ-40346527, or at least 95% identical to the CDRs of BLZ945, or at least 95% identical to the CDRs of Emactuzumab, or at least 95% identical to the CDRs of AMG820, or at least 95% identical to the CDRs of IMC-CS4, or at least 95% identical to the CDRs of Cabiralizumab; or wherein the antibody or active fragment thereof is at least one antibody comprising Ipilimumab, Nivolumab, Cemiplimab, Pembrolizumab, Atezolizumab, Avelumab, Durvalumab, Pexidartinib, PLX7486, ARRY-382, JNJ-40346527, BLZ945, Emactuzumab, AMG820, IMC-CS4 and Cabiralizumab.

7 . The extracellular vesicle of claim 4 , further comprising PTGFRN or a fragment thereof, wherein the antibody or fragment thereof is fused to the PTGFRN or fragment thereof.

8 . A pharmaceutical composition comprising the extracellular vesicle of claim 1 .

9 . A method of treating a disease in a subject in need thereof comprising administering the extracellular vesicle of claim 1 to the subject, thereby treating the disease in the subject.

10 . The method of claim 9 , wherein the disease is a cancer.

11 . The extracellular vesicle of claim 1 , wherein the single-stranded ASO further comprises a cholesterol tag at the 5′ or 3′ end.

12 . The extracellular vesicle of claim 1 , wherein the single-stranded antisense oligonucleotide (ASO) consists of SEQ ID NO: 1, SEQ ID NO: 2, or SEQ ID NO: 4.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 31, 2023
From: SATHYANARAYANAN, SRIRAM; WILLIAMS, DOUGLAS E.; BURZYN, DALIA; BOUTIN, ADAM THOMAS; KAMERKAR, SUSHRUT
To: CODIAK BIOSCIENCES, INC.
Reel/Frame 064767/0110 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 11, 2023
From: CODIAK BIOSCIENCES, INC.
To: LONZA SALES AG
Reel/Frame 064251/0794 →
Continuity (3)
Continuation 16969511
Provisional Application 62629563 · Feb 12, 2018
Related Publication 20230365971A1 · Nov 16, 2023
References Cited (76)
US 7517644B1 · Smith · 2009 [cited by examiner]
US 10195290B1 · Dooley et al. · 2019 [cited by applicant]
US 11512315B2 · Sathyanarayanan et al. · 2022 [cited by applicant]
US 20040220393A1 · Ward · 2004 [cited by examiner]
US 20050074879A1 · Karras · 2005 [cited by examiner]
US 20160243192A1 · Seeger · 2016 [cited by examiner]
US 20160346334A1 · Trujillo · 2016 [cited by examiner]
WO WO2005116210A2 · 2005 [cited by examiner]
WO 2010115202A2 · 2010 [cited by applicant]
WO 2014082083A1 · 2014 [cited by applicant]
WO WO2016201323A1 · 2016 [cited by examiner]
WO 2017053722A1 · 2017 [cited by applicant]
WO 2017161010A1 · 2017 [cited by applicant]
WO 2018039119A1 · 2018 [cited by applicant]
WO WO2019040920A1 · 2019 [cited by examiner]
WO 2019157535A1 · 2019 [cited by applicant]
Machine translation of WO2005116210, pp. 1-5 (Year: 2005). [cited by examiner]
GenBank NM_005194.4 , NM_005194.4 GenBank, 1991, pp. 1-11 (Year: 1991). [cited by examiner]
NM_001369518.1, GenBank, 1987, pp. 1-9 (Year: 1987). [cited by examiner]
Ambros et al., “A Uniform System for Microrna Annotation,” RNA 9(3):277-279 (2003). [cited by applicant]
Aranda et al., “Trial Watch: Immunostimulatory Monoclonal Antibodies in Cancer Therapy,” Oncoimmunology 3(1):e27297 (2014). [cited by applicant]
Bacchetti at al., “Transfer of the Gene for Thymidine Kinase to Thymidine Kinase-deficient Human Cells by Purified Herpes Simplex Viral DNA,” Proceedings of the National Academy of Sciences 74(4):1590-1594 (1977). [cited by applicant]
Bartel, “MicroRNAs: Genomics, Biogenesis, Mechanism, and Function,” Cell 116(2):281-297, Elsevier (2004). [cited by applicant]
Cannarile et al., “Colony-stimulating Factor 1 Receptor (Csf1 r) Inhibitors in Cancer Therapy,” Journal for immunotherapy of cancer 5(1):53 (2017). [cited by applicant]
Chalasani et al., “The Diagnosis and Management of Nonalcoholic Fatty Liver Disease: Practice Guidance From the American Association for the Study of Liver Diseases,” Hepatology 67(1):328-357 (2018). [cited by applicant]
Child et al., “Acyl Selectivity in the Transfer of Molecular Species of Phosphatidylcholines From Human Erythrocytes,” Biochimica et Biophysica Acta 812(2):321-332 (1985). [cited by applicant]
Cuccarese et al., “Heterogeneity of Macrophage Infiltration and Therapeutic Response in Lung Carcinoma Revealed by 3d Organ Imaging,” Nature Communications 8: 14293 (2017). [cited by applicant]
Elbashir et al., Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells, Nature 411 (6836):494-498 (2001). [cited by applicant]
Felgner et al., “Enhanced Gene Delivery and Mechanism Studies With a Novel Series of Cationic Lipid Formulations,” Journal of Biological Chemistry 269(4):2550-2561, American Society for Biochemistry and Molecular Biolog… [cited by applicant]
Felgner et al., “Lipofection: a Highly Efficient, Lipid-mediated Dna-transfection Procedur,” Proceedings of the National Academy of Sciences of the United States of America 84(21): 7 413-7417, National Academy of Scienc… [cited by applicant]
Funes S.C., et al., “Implications of Macrophage Polarization in Autoimmunity,” Immunology 154(2):186-195, Blackwell Scientific Publications, England (Jun. 2018). [cited by applicant]
Furuta, Y., et al., “Favipiravir (T-705), a Novel Viral RNA Polymerase Inhibitor,” Antiviral Research 100(2): 446-454, Elsevier B.V (Nov. 2013). [cited by applicant]
Gautier E.L., et al., “Gene-expression Profiles and Transcriptional Regulatory Pathways That Underlie the Identity and Diversity of Mouse Tissue Macrophages,” Nature immunology 13(11):1118-1128, Nature America Inc, Unit… [cited by applicant]
Goodchild J., et al., “Therapeutic Oligonucleotides,” Methods in molecular biology 764:1-15, Humana Press, United states (2011). [cited by applicant]
Gross, T.J and Hunninghake, G.W., “Idiopathic PulmonaryFibrosis, ”The New England Journal of Medicine345(7):517-525 MassachusettsMedical Society, United States (Aug. 2001). [cited by applicant]
Guerriero J.L., et al., “Class IIa Hdac Inhibition Reduces Breast Tumours and Metastases Through Anti-tumour Macrophages,” Nature 543(7645):428-432, Macmillan Journals Itd, England (Mar. 2017) with Supplemental Informat… [cited by applicant]
International search report and Written opinion for the application PCT/US2019/017731 mailed on Jul. 25, 2019, 19 pages. [cited by applicant]
Kahlert, C., et al., “Identification of Double-Stranded Genomic DNA Spanning all Chromosomes with Mutated Kras and P53 Dna in the Serum Exosomes of Patients with Pancreatic Cancer,” Journal of Biological Chemistry 289(7… [cited by applicant]
Krausgruber T., et al., “Irf5 Promotes Inflammatory Macrophage Polarization and Th1-th17 Responses,” Nature immunology 12(3):231-238, Nature America Inc, United states (Mar. 2011). [cited by applicant]
Lewis C.E., and Pollard J.W., “Distinct Role of Macrophages in Different Tumor Microenvironments,” Cancer Research 66(2):605-612, Cancer research (Jan. 2006). [cited by applicant]
Liu Y.C., et al., “Macrophage Polarization in Inflammatory Diseases,” International journal of biological sciences 10(5):520-529, Ivyspring International, Australia (May 2014). [cited by applicant]
Ma L., et al., “On the Classification of Long Non-coding Rnas,” RNA biology 10(6):925-933, Landes Bioscience, United states (Jun. 2013). [cited by applicant]
Martinez F.O., and Gordon S., “The M1 and M2 Paradigm of Macrophage Activation: Time for Reassessment,” F1000prime reports 6:13, Faculty of 1000, England (Mar. 2014). [cited by applicant]
Mayo Clinic Staff., “Definition [of pulmonary fibrosis] Mayo Foundation for Medical Education and Research,” Retrieved Jul. 26, 2014, available from the world wide at webmayoclinic.org/diseases-conditions/pulmonary-fibr… [cited by applicant]
Mills C.D., et al., “M-1/m-2 Macrophages and the Th1/th2 Paradigm,” Journal of immunology 164(12):6166-6173, American Association of Immunologists, United states (Jun. 2000). [cited by applicant]
Mosser, D.M and Edwards, J.M., “Exploring the Full Spectrum of Macrophage Activation,” Nature reviews Immunology 8(12):958-969, Nature Publishing Group, England (Dec. 2008). [cited by applicant]
Murray P.J., et al., “Macrophage Activation and Polarization: Nomenclature and Experimental Guidelines,” Immunity 41 (1):14-20, Cell Press, United states (Jul. 2014). [cited by applicant]
Nakada Y., et al., “Antisense Oligonucleotides Specific to Mutated K-ras Genes Inhibit Invasiveness of Human Pancreatic Cancer Cell Lines,” Pancreatology 1 (4):314-319, Elsevier (2001). [cited by applicant]
Neumann E., et al., “Gene Transfer Into Mouse Lyoma Cells by Electroporation in High Electric Fields,” The EMBO journal 1 (7): 841-845, Wiley Blackwell, England (1982). [cited by applicant]
Paddison P. J., et al., “Short Hairpin Rnas (Shrnas) Induce Sequence-specific Silencing in Mammalian Cells,” Genes & development 16(8):948-958, Cold Spring Harbor Laboratory Press, United states (Apr. 2002). [cited by applicant]
Papapetrou, P.U., et al.,“Genetic Modification of Hematopoietic Stem Cells With Nonviral Systems: Past Progress and Future Prospects,” Gene Therapy 12(Suppl 1):S118-S130, Nature Publishing Group, England(Oct. 2005). [cited by applicant]
Pardoll D.M., “The Blockade of Immune Checkpoints in Cancer Immunotherapy,” Nature reviews Cancer 12(4):252-264, Nature Pub, England (Mar. 2012). [cited by applicant]
Patel S., and Player M.R., “Colony-stimulating Factor-1 Receptor Inhibitors for the Treatment of Cancer and Inflammatory Disease,” Current topics in medicinal chemistry 9(7):599-610, Bentham Science Publishers, UAE (200… [cited by applicant]
Petersen, Mand Wengel, G., “LNA: a Versatile Tool forTherapeutics and Genomics,” Trends in Biotechnology 21 (2):74-81, ElsevierScience Publishers, England (Feb. 2003). [cited by applicant]
Rejiba, S., et al., “KDRas Oncogene Silencing Strategy Reduces Tumor Growth and Enhances Gemcitabine Chemotherapy Efficacy for Pancreatic Cancer Treatment,” Cancer Science 98(7):1128-1136, Japanese Cancer Association (J… [cited by applicant]
Rodell C.B., et al., “TLR7/8-agonist-loaded Nanoparticles Promote the Polarization of Tumour-associated Macrophages to Enhance Cancer Immunotherapy,” Nature Biomedical Engineering 2:578-588, Springer Nature, England(201… [cited by applicant]
Roszer T., “Understanding the Mysterious M2 Macrophage Through Activation Markers and Effector Mechanisms,” Mediators of inflammation, 816460, Rapid Communications of Oxford Ltd, United states (2015). [cited by applicant]
Sambrook, J., et al., “Molecular Cloning: A Laboratory Manual,” Second Edition, Cold Spring Harbor Laboratory Press, United States (1989). [cited by applicant]
Sau S., et al., “Multifunctional Nanoparticles for Cancer Immunotherapy: a Groundbreaking Approach for Reprogramming Malfunctioned Tumor Environment,” Journal of Controlled Release 27 4:24-34, Elsevier (Mar. 2018). [cited by applicant]
Selvam C., et al., “Therapeutic Potential of Chemically Modified Sirna: Recent Trends,” Chemical biology & drug design 90(5):665-678, Wiley-Blackwell, England (Nov. 2017). [cited by applicant]
Senti G., et al., “Intralymphatic Allergen Administration Renders Specific Immunotherapy Faster and Safer: a Randomized Controlled Trial,” PNAS 105(46):17908-17912 (Apr. 2008). [cited by applicant]
Sharei A., et al., “A Vector-free Microfluidic Platform for Intracellular Delivery,” Proceedings of the National Academy of Sciences 110(6):2082-2087, National Academy of Sciences, United States (Feb. 2013). [cited by applicant]
Sica A., et al., “Autocrine Production of IL-10 Mediates Defective IL-12 Production and NF-KB Activation in Tumor-Associated Macrophages,” Journal of Immunology 164 (2):762-767, (Jan. 2000). [cited by applicant]
Sica A., et al., “Macrophage Polarization in Tumour Progression,” Seminars in cancer biology 18(5):349-355, Academic Press, England (Oct. 2008). [cited by applicant]
Song Y., et al., “Ultrasound-mediated Dna Transfer for Bacteria,” Nucleic acids research 35(19):e129, Oxford University Press, England (2007). [cited by applicant]
Storz P., “The Crosstalk Between Acinar Cells With Kras Mutations and M1-polarized Macrophages Leads to Initiation of Pancreatic Precancerous Lesions,” Oncoimmunology 4(6): e1008794, Landes Bioscience, United states (Ju… [cited by applicant]
Su M.J., et al., “Pancreatic Cancer Cell Exosome-mediated Macrophage Reprogramming and the Role of Micrornas 155 and 125b2 Transfection Using Nano particle Delivery Systems,” Scientific Reports, 6:30110, (Jul. 2016). [cited by applicant]
Summerton, J. and Weller, D., “Morpholino Antisense Oligomers: Design, Preparation, and Properties,” Antisense & Nucleic Acid Drug Development 7(3):187-195, Mary Ann Liebert, Inc., United States (Jun. 1997). [cited by applicant]
Vickers et al., Efficient Reduction of Target RNAs by Small Interfering RNA and RNase H-dependent Antisense Agents, The Journal of Biological Chemistry, 2003, vol. 278, No. 9: 7108-7118 (Year:2003). [cited by applicant]
Wang Q., et al., “Fra-1 Protooncogene Regulates 11-6 Expression in Macrophages and Promotes the Generation of M2d Macrophages,” Cell Research 20(6):701-712, Nature Publishing Group, England(Jun. 2010). [cited by applicant]
Weiss B., et al., “Antisense Oligodeoxynucleotides and Antisense RNA: Novel Pharmacological and Therapeutic Agents,” CRC-Press, 252 (1997). [cited by applicant]
Wynn T.A., et al., “Macrophage Biology in Development, Homeostasis and Disease,” Nature 496(7446):445-455, Nature Publishing Group, England (Apr. 2013). [cited by applicant]
Xue J., et al., “Alternatively Activated Macrophages Promote Pancreatic Fibrosis in Chronic Pancreatitis,” Nature Communications 6:7158 (May 2015). [cited by applicant]
Xue J., et al., “Transcriptome-based Network Analysis Reveals a Spectrum Model of Human Macrophage Activation,” Immunity 40(2):274-288, Cell Press, United states (Feb. 2014). [cited by applicant]
Zeisberger, S.M., et al., “Clodronate-liposome-mediated Depletion of Tumour-associated Macrophages: a New and Highly Effective Antiangiogenic Therapy Approach,” British Journal of Cancer 95(3):272-281, Nature Publishing… [cited by applicant]
Zhang Y., et al., “Adipocyte-derived Microvesicles From Obese Mice Induce M1 Macrophage Phenotype Through Secreted Mir-155,” Journal of Molecular Cell Biology 8(6):505-517, Chinese Academy of Sciences (Dec. 2016). [cited by applicant]